This latest meeting of the AACR painted a broad picture other chemotherapeutic agents. I Usami (Kyoto University, Japan) showed that pretreatment of a cell line with of cancer research, from the preclinical and clinical studies with new antitumor agents to radiation biology and a potent tyrosine kinase inhibitor, herbimycin A, suppressed the appearance of apoptosis. molecular biology with special emphasis on oncogenes and tumor suppressor genes. New reasons for hope in Inherited susceptibility to cancer was initially recognized through observations that virtually all cancers tend cancer treatment were also given. The meeting also benefited from the introduction of high quality presentations to aggregate in families, as explained by F Li (Dana Farber Cancer Institute, Boston, MA). The first inherited in many sessions. During the meeting 4290 abstracts were presented.
cancer predisposing gene, the RB1 gene for hereditary retinoblastoma, was cloned in 1986. Since then several The comprehension of the genetic predisposition to cancer was a recurring theme with, as an introduction, a dozen inherited susceptibility genes have been identified, creating the opportunity to target early interventions in provocative talk by L Strong (Anderson Cancer Center, Houston, TX) named 'Cancer genetics is a little like these high risk populations. Germline mutations in another gene, p53, predisposes to diverse childhood caninsanity, we have gotten it from our kids' and focused on genetic studies on childhood cancer and whether genetic cers as well as breast cancer in young women (J Fruehauf, University of California; L Meng, University of Miami), abnormalities could be generalized to all childhood cancers. She showed that many of the fundamental concepts bladder cancer (P Keohavong, University of Pittsburg) and ovarian cancer (R Gibb and C Yashar, University of Louisof cancer susceptibility and tumor suppressor genes are common in childhood cancers but that the cancer suscepville; R DiCioccio, Roswell Park Cancer Institute, New York). Among inherited susceptibility genes for adulttibility is increasingly complex with evidence of genetic heterogeneity.
onset cancers which also predispose to multiple cancers, some of them including the APC gene for familial Several presentations highlighted the possible clinical utility of new components in the diagnosis and clinical polyposis coli, mismatch repair genes (MSH2, MLH1, PMS1/2) for hereditary non-polyposis colon cancer, trials. D Von Hoff (University of Texas) pointed out that the discovery of new anticancer agents with unique patched gene for nevoid basal cell carcinoma syndrome, and RET gene for multiple endocrine neoplasia type II mechanisms of action provides opportunities to help patients suffering from cancer. However, as brilliant as and related disorders (S Egawa, National Cancer Center Research Institute, Tokyo, Japan) were discussed. B the clinical science is, many of the new agents which are brought into clinical trial do not appear to work as well Ponder (Cambridge, UK) and B Weber (University of Pennsylvania), described the efforts to identify and as they did in the preclinical systems. D Von Hoff gave a list of the principles which should carefully be followed understand breast cancer susceptibility genes, such as BRCA1 and BRCA2. These genes offer the opportunity to in order to maximize the chances of a new agent working in the clinic. The relationship between the treatment with screen for predisposition to a major killer, information that might prove useful in early detection and/or prevenanticancer drugs and apoptosis was investigated by H Seimiya (University of Tokyo, Japan). In this study, while tion. Ovarian cancer has also been shown to be linked to mutations of BRCA1 and to a lesser extent, BRCA2 as etoposide or camptothecin (two topoisomerase II inhibitors) enhanced apoptosis, phorbol ester-resistant explained by H Lynch (University of Omaha). Prostate cancer has been outlined by W Isaacs (Johns Hopkins, cells displayed a decreased susceptibility to apoptosis induced by these drugs. Furthermore, Z-Asp, a preferenBaltimore) who showed that a major prostate cancer susceptibility allele, designated HPC1 has been discovered tial inhibitor of proteases blocked the apoptosis (a form of cell death). L Smith (University of California) showed and localized at chromosome 1q24-25. T Gilmer (Glaxo Wellcome, NC, USA) and collaborators that paclitaxel (a microtubule inhibitor) and topotecan (a topoisomerase I inhibitor) induced early apoptosis and addressed the targeting signal transduction pathways as anticancer therapy. The importance of tyrosine kinases in that 5-fluorouracil (inhibitor of RNA transcription), gemcitabine and tamoxifen had insignificant effects on signal transduction and the association of aberrant kinase activity with proliferative disorders make agents that apoptosis. He concluded by saying that the induction of apoptosis by paclitaxel and topotecan could be used to modulate tyrosine kinase pathways attractive pharmacological probes and potential therapeutic agents. They enhance the antineoplastic effect of radiation therapy or have identified a novel signal transduction inhibitor GW opment, cellular senescence and cancer. Y Hashimoto and colleagues (University of Nagoya, Japan) have shown 7072X, which was able to penetrate cells, selectively kill tumor cells and decrease phosphotyrosine on specific that p21, p27 and p57 share a common amino acid sequence. M Bani (Sunnybrook Health Science Centre, proteins. This inhibitor can kill various human tumor cell lines, arrest normal human cell cultures in vitro and Toronto, Canada) and A Sgambato (Columbia University, New York) showed that overexpression of p27 is associainhibits a human tumor xenograft growing in nude mice. J Woodburn and colleagues (Zeneca Pharmaceuticals, ted with an enhanced survival rate during melanoma progression and that a deregulation of its expression is Cheshire, UK) described a new epidermal growth factor tyrosine kinase inhibitor, named ZD 1839 which shows observed in human breast cancer. It is becoming increasingly clear that the human popuantitumor activity in a broad range of human solid tumor xenografts implanted in nude mice and is well tolerated lation is not homogeneous in its response to ionizing radiations. There is some evidence, for example, of a for up to 4 months of therapy. J Isaacs (Johns Hopkins), highlighted the presence of TRKA expression in prostate sensitive group of individuals amongst the Japanese survivors who developed breast cancer early. There is cancer and the development of a TRK selective tyrosine kinase inhibitor, CEP-751 as a potential therapeutic agent mounting evidence that individuals heterozygous for ataxia telangiectasia, as well as being more likely to for the treatment of prostate cancer and which exhibits remarkable properties so far in animal trials. N Rosen develop cancer spontaneously, are also more sensitive to radiation induced cancer. Other genetically predisposed (Sloan-Kettering Cancer Center, New York) showed that the farnesylation of RAS acts in inhibiting tumor cell groups are likely to be identified in the future. The radiation risk estimates used at present assume a uniform growth.
The presence of shortened telomeres and the telomerradiosensitivity and this may well prove to be very misleading (E Hall, Columbia University). ase activity have been shown to be present in most primary human tumors but not in somatic tissues (J Shay, Irradiation of normal eukaryotic cells results in delayed progression through the G1, S and G2 phases of the cell University of Texas). Telomeres are essential for stable chromosome maintenance. The key clinical challenge is cycle. The G1 arrest is regulated by the p53 tumor suppressor gene product. Irradiation results in increased to determine if knowledge of telomerase activity has diagnostic or prognostic utility. What one already knows expression of p53, which in turn induces the production of p21. Y Lee (Korea Cancer Center Hospital, Seoul, South is that in certain cancers (eg neuroblastoma and meningiomas) knowledge of telomerase activity may Korea) showed that low-dose gamma-ray pre-irradiation reduces apoptosis in both normal mouse lymphocytes help in identifying patients who would either have favorable or poor prognostic outcomes (C Poremba, University and mouse lymphoma cells through different mechanisms. The reduction of apoptosis by low-dose preof Mü nster, Germany), while in other instances (eg pancreas), a study of the telomerase activity could help irradiation was via p53-dependent pathway in normal lymphocytes but p53-independent pathway in mouse to distinguish between benign and malignant lesions (E Hiyama, University of Hiroshima, Japan). lymphoma cells, which means that the apoptosis pathway may be different between normal and tumor cells. Another area of concern was apoptosis or programmed cell death. Apoptosis is required for the maintenance of J Yahalom (Memorial Sloan-Kettering Cancer Center) highlighted the fact that radiation-induced micronucleus normal tissue homeostasis, a careful balance between proliferation versus cell death. The newly discovered formation is cell cycle dependent and that S-phase cells are the most sensitive population. D Banerjee (Memorial gene, Bcl-2, has the novel function of blocking the programmed death of cells rather than promoting their Sloan-Kettering Cancer Center), highlighted the fact that radiation damage led to the induction of the excision growth. When deregulated, Bcl-2 extends the survival of cells normally destined to die (S Korsmeyer, Howard repair gene ERCC1 in HL60 cells. A particular emphasis was also given to the use of aniHughes Medical Institute, St Louis, MO). Bcl-2 does not act alone but duels with its counteracting twin, a partner mal models in the study of human tumor development. T Jacks (Howard Hughes Medical Institute, Cambridge, known as Bax. When Bax is in excess, cells execute a death command, but when Bcl-2 dominates, the pro-MA) gave a talk about the tumor suppressor gene mutations in mice while T Van Dycke (Department of Biogramme is interrupted and cells survive. In breast cancer cells, T Wang (National Cancer Institute, Frederick, MD) chemistry, Chapel Hill, NC) was interested in the elucidation of a p53 tumor suppression mechanism using anisuggested that multiple signaling pathways regulate the Bcl-2/Bax apoptosis pathway and that the protective mal models. In humans, inheritance of a defective allele of a tumor suppressor gene strongly predisposes to effects of estradiol on cytotoxicity from specific chemotherapeutic agents such as adriamycin or etoposide may tumor development. Similarly, mice heterozygous for a mutation in Rb, p53, Nf1 or Nf2 are cancer prone. Primary depend on the effects of these agents on the Bcl-2/Bax apoptosis pathway. In myeloma cells, the relative levels cells and cell lines isolated from different mutant strains have also been proven to be very useful in the analysis of Bcl-2 appear to determine their ability to undergo apoptosis (D Siegel, Sloan-Kettering Cancer Center).
of tumor suppressor gene function. For example, cells lacking p53 are defective in G1 arrest or apoptosis in Cyclin-dependent kinases (cdk) and cyclins are required for cell cycle. Cyclin dependent kinase inhibitors response to DNA damage or other adverse conditions. In an effort to understand the mechanism of action of p53, (p21, p27, p57) inhibit the activity of several cyclin dependent kinases, in contrast to other inhibitors such as p15 the p21 gene, which is known to be induced by p53 following DNA damage, has been targeted and has been and p16 which act on specific cyclin-cdk complexes (P Zhang, Einstein College of Medicine, New York). These shown to be a key component of the p53-dependent growth arrest pathway but not to be required for p53-inhibitors have been implicated in responses to DNA damage, growth control and differentiation during develdependent apoptosis. A combined evaluation of p53 and p21 expression strongly correlates with disease pro-S Baatout Laboratory of Radiobiology gression and prognosis in several types of cancers as shown by M Ogawa (Osaka University, Japan) and by Belgian Nuclear Energy Study Center CEN-SCK G Roddey (Anderson Cancer Center, Houston, TX).
In conclusion, the meeting highlighted the tremendous Boeretang 200 B-2400 Mol progress and promise in understanding malignancy in general. This was an extremely interesting meeting, Belgium where the quality of talks and posters was high, the discussions animated and the sense of progress invigorating. It also provided a good opportunity for people working in diverse fields but with an overall interest in cancer to get together and see things from different points of view.
